Metrelef (Buserelin Acetate)

Buserelin acetate is a synthetic GnRH agonist that first stimulates, then desensitises pituitary GnRH receptors. This leads to an initial rise in LH and FSH followed by a sustained decline, reducing downstream sex‑steroid production and suppressing hormone‑driven disease processes.

The specific dose and administration schedule of Metrelef are determined by the prescribing clinician based on the individual’s diagnosis, disease severity, and response to therapy. Patients should follow the exact regimen provided by their healthcare professional.

Metrelef is contraindicated in pregnancy because it suppresses sex‑steroid production, which can harm fetal development. Its safety during breastfeeding has not been established, and women should discuss alternative options with their physician if they are pregnant or nursing.

To order Metrelef, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Metrelef (buserelin acetate) is similar in mechanism to other GnRH agonists such as leuprorelin and goserelin, offering nasal administration rather than injectable forms. This route can improve patient convenience, though efficacy and safety profiles are comparable across the class when used appropriately.

Metrelef nasal spray should be stored at room temperature, preferably below 25 °C. Keep the device in its original packaging, protect it from moisture and direct sunlight, and avoid freezing to maintain product stability.

Metrelef is delivered as a nasal spray. The patient sprays the prescribed number of sprays into each nostril according to the prescriber’s instructions, typically after priming the device. Proper technique ensures consistent dosing and optimal therapeutic effect.

Serious risks include severe allergic reactions (anaphylaxis), pituitary apoplexy, significant hypotension, cardiac arrhythmias, and adrenal insufficiency. Patients should be monitored closely for any signs of these events and seek immediate medical attention if they occur.

Metrelef should not be used by individuals with known hypersensitivity to buserelin acetate or any formulation components, patients with uncontrolled cardiovascular disease, those who are pregnant, or anyone for whom hormonal suppression is contraindicated without appropriate medical supervision.